Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update announcing ongoing recruitment for Sefaxersen (RO7434656) in adults with high-risk primary IgA nephropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Sefaxersen (RO7434656)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Primary IgA Nephropathy | Phase 3 | Status: RECRUITING